LBL.V - Lattice Biologics Ltd.
| Previous Close | 0.0650 |
| Open | 0.0700 |
| Bid | 0.0650 x N/A |
| Ask | 0.0750 x N/A |
| Day's Range | 0.0650 - 0.0750 |
| 52 Week Range | 0.0200 - 0.2100 |
| Volume | 272,386 |
| Avg. Volume | 569,219 |
| Market Cap | 7.715M |
| Beta (5Y Monthly) | -13.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Feb. 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Lattice Biologics Eliminates CAN$838,000 in Debt
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.
- Business Wire
Lattice Biologics Ltd. Reports Second Quarter 2020 Results
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for Q2 2020
- Business Wire
Lattice Biologics Update
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce the addition of Chad Green, RRT, to the clinical development team. Mr. Green is a registered respiratory therapist, and President- elect of the Montana chapter of respiratory therapists. Mr. Green is assisting in patient evaluation, telemedicine, treatment, and monitoring of patients as they undergo treatment for the COVID-19 Phase 1 trial.
- Business Wire
Lattice Biologics Ltd. Announces Option Repricing
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces that the Company has repriced the strike price of the 3 million stock options originally to be granted to Directors and Employees announced on March 16, 2020 to $.095 from $.075 due to recent market activity. The options will have an exercise term of five years from the date of grant.
- Business Wire
Lattice Biologics Signs Definitive Agreement with Alumina Partners for $6 Million At-Will Offering Facility
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") is pleased to announce that it has entered into a definitive agreement (the "Agreement") with Alumina Partners (Ontario) Ltd. ("Alumina") for a commitment of up to $6,000,000 CDN (six million dollars) in an at-will offering facility (the "Facility"). This facility replaces the previously announced private placement announced on March 17th, 2020.
- Business Wire
Lattice Biologics Ltd. Announces Initial Recruitment of Patients for a Phase 1 Clinical Trial to Access Safety and Efficacy of AmnioBoost for Treatment of COVID-19
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection.
- Business Wire
Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") today announced that it plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19)
- Business Wire
Lattice Biologics Announces Planned Debt-to-Equity Conversion
Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) ("Lattice Biologics" or the "Company") announces that, subject to TSXV approval, the Company plans to convert US $726,200 (Can$1,000,000) of debt (the "Debt") into equity of Lattice Biologics (the "Transaction").
- Business Wire
LATTICE BIOLOGICS LTD. Transferred To TSX Venture Exchange Tier 2
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") Lattice Biologics Ltd. announces today that its listing on the TSX Venture Exchange ("TSX-V") has been transferred from the Tier 1 category to the Tier 2 category effective March 5, 2020
- Simply Wall St.
Did Changing Sentiment Drive Lattice Biologics's (CVE:LBL) Share Price Down A Painful 90%?
It's not possible to invest over long periods without making some bad investments. But really big losses can really...
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Lattice Biologics Ltd. (CVE:LBL)?
If you're interested in Lattice Biologics Ltd. (CVE:LBL), then you might want to consider its beta (a measure of share...
